Immunosuppressants/Immunomodulators and Malignancy.

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immunosuppression elevates malignancy risk due to weakened tumor immunity and viral activation.
• Malignancies in immunosuppressed individuals are often aggressive and virus-associated.
• Immunosuppressive agents influence cancer type, frequency, and clinicopathological features.

Purpose of the Study:

• To explore the evolving clinicopathological characteristics of immunosuppressive neoplasms, specifically lymphoproliferative disorders (LPDs).
• To understand how different immunosuppressants/immunomodulators affect post-transplant LPD and rheumatoid arthritis-associated LPD (RA-LPD).

Main Methods:

• Review of existing literature on immunosuppression and malignancy.
• Analysis of clinicopathological features of LPDs in organ transplant recipients and RA patients.
• Correlation of LPD characteristics with specific immunosuppressive drug regimens.

Main Results:

• Post-transplant malignancies vary based on immunosuppressive drug type.
• Methotrexate (MTX) is linked to MTX-associated LPD.
• RA-LPD features differ based on co-administered anti-RA agents like tacrolimus and TNF inhibitors.

Conclusions:

• Clinicopathological characteristics of post-transplant LPD and RA-LPD are dynamic and influenced by immunosuppressive/immunomodulatory agents.
• Understanding these evolving trends is crucial for effective clinical management of immunosuppressive neoplasms.